Abstract
The blood-brain barrier (BBB) effectively prevents microtubule (MT)-stabilizing drugs from readily entering the central nervous system (CNS). A major limiting factor for microtubule-stabilizing drug permeation across the BBB is the active efflux back into the circulation by the overexpression of the multidrug-resistant gene product 1 (MDR1) or P-glycoprotein (P-gp). This study has focused on strategies to overcome P-gp-mediated efflux of Taxol analogs, MT-stabilizing agents that could be used to treat brain tumors and, potentially, neurodegenerative diseases such as Alzheimer’s disease. However, taxol is a strong P-gp substrate that limits its distribution across the BBB and therapeutic potential in the CNS. We have found that addition of a succinate group to the C-10 position of paclitaxel (Taxol) results in an agent, Tx-67, with reduced interactions with P-gp and enhanced permeation across the BBB in both in vitro and in situ models. Our studies demonstrate the feasibility of making small chemical modifications to Taxol to generate analogs with reduced affinity for the P-gp but retention of MT-stabilizing properties, i.e., a taxane that may reach and treat therapeutic targets in the CNS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Audus K. L. and Borchardt R. T. (1987) Bovine brain microvessel endothelial cell monolayers as a model system for the blood-brain barrier. Ann. NY Acad. Sci. 507, 9–18.
Audus K. L., Ng L., Wang W., and Borchardt R. T. (1996) Brain microvessel endothelial cell culture systems. Pharm. Biotechnol. 8, 239–258.
Brouty-Boye D., Kolonias D., Wu C. J., Savaraj N., and Lampidis T. J. (1995) Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux. Cancer Res. 55, 1633–1638.
Cahan M. A., Walter K. A., Colvin O. M., and Brem H. (1994) Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother. Pharmacol. 33, 441–444.
Cordon-Cardo C., O’Brien J. P., Casals D., Rittman-Grauer L., Biedler J. L., Melamed M. R., and Bertino J. R. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86, 695–698.
Desnottes J. F. (1996) New targets and strategies for the development of antibacterial agents. Trends Biotechnol. 14, 134–140.
Fellner S., Bauer B., Miller D.S., Schaffrik M., Franhanel M., Spruss T., et al. (2002) Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest. 110, 1309–1318.
Gottesman M. M., Pastan I., and Ambudkar S. V. (1996) P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev. 6, 610–617.
Greig N. H., Soncrant T. T., Shetty H. U., Momma S., Smith Q. R., and Rapoport S. I. (1990) Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother. Pharmacol. 26, 263–268.
Lovich M. A., Creel C., Hong K., Hwang C. W., and Edelman E. R. (2001) Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J. Pharm. Sci. 90, 1324–1335.
Mann H., Ladenheim B., Hirata H., Moran T. H., and Cadet J. L. (1997) Differential toxic effects of methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) in multidrug resistant (mdr1a) knockout mice. Brain Res. 769, 340–346.
Michaelis M. L., Chen Y., Hill S., Reiff E., Georg G., Rice A., and Audus K. L. (2002) Amyloid peptide toxicity and microtubule-stabilizing drugs. J. Mol. Neurosci. 19, 101–105.
Michaelis M. L., Ranciat N., Chen Y., Bechtel M., Ragan R., Hepperle M., et al. (1998) Protection against β-amyloid toxicity in primary neurons by paclitaxel (Taxol). J. Neurochem. 70, 1623–1627.
Ojima I. and Slater J. C. (1997) Synthesis of novel 3′-trifluoromethyl taxoids through effective kinetic resolution of racemic 4-CF3-beta-lactams with baccatins. Chirality 9, 487–494.
Ojima I., Slater J. C., Michaud E., Kuduk S. D., Bounaud P. Y., Vrignaud P., et al. (1996) Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. J. Med. Chem. 39, 3889–3896.
Pardridge W. M. (2002) Targeting neurotherapeutic agents through the blood-brain barrier. Arch. Neurol. 59, 35–40.
Rose J. M., Peckham S. L., Scism J. L., and Audus K. L. (1998) Evaluation of the role of P-glycoprotein in ivermectin uptake by primary cultures of bovine brain microvessel endothelial cells. Neurochem. Res. 23, 203–209.
Schinkel A. H. (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 36, 179–194.
Siegal T. and Zylber-Katz E. (2002) Strategies for increasing drug delivery to the brain: focus on brain lymphoma. Clin. Pharmacokinet. 41, 171–186.
Smith Q. (1996) Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. Pharm. Biotechnol. 8, 285–307.
Taylor E. M. (2002) The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin. Pharmacokinet. 41, 81–92.
Tsuji A., Terasaki T., Takabatake Y., Tenda Y., Tamai I., Yamashima T., et al. (1992) P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51, 1427–1437.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rice, A., Michaelis, M.L., Georg, G. et al. Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors. J Mol Neurosci 20, 339–343 (2003). https://doi.org/10.1385/JMN:20:3:339
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/JMN:20:3:339